ArticleF1000Research
Computational screening for potential drug candidates against the SARS-CoV-2 main protease.
Article in F1000Research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- The Spike of SARS-CoV-2: Uniqueness and Applications.Frontiers in immunology · 2021Pooled it
- Under ONIOM Layers: Analysis of BCR-ABL Enzyme Inhibitors Through Bond-Critical Points and Natural Orbitals.Molecules (Basel, Switzerland) · 2025Article
- Article
- Identification of and Mechanistic Insights into SARS-CoV-2 Main Protease Non-Covalent Inhibitors: An In-Silico Study.International journal of molecular sciences · 2023Article
- Natural therapeutics against SARS CoV2: the potentiality and challenges.Vegetos (Bareilly, India) · 2023Review
- Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of natural compounds against the SARS-CoV-2 main-protease.Journal of biomolecular structure & dynamics · 2022Article
- In silico investigation of potential inhibitors to main protease and spike protein of SARS-CoV-2 in propolis.Biochemistry and biophysics reports · 2021Article
- Therapeutics for COVID-19: from computation to practices-where we are, where we are heading to.Molecular diversity · 2021Review
- Prospective Role of Peptide-Based Antiviral Therapy Against the Main Protease of SARS-CoV-2.Frontiers in molecular biosciences · 2021Article
- Consensus virtual screening of dark chemical matter and food chemicals uncover potential inhibitors of SARS-CoV-2 main protease.RSC advances · 2020Article
- Computation screening and molecular docking of FDA approved viral protease inhibitors as a potential drug against COVID-19.Gastroenterology and hepatology from bed to bench · 2020Article
- Computer-Aided Analysis of Multiple SARS-CoV-2 Therapeutic Targets: Identification of Potent Molecules from African Medicinal Plants.Scientifica · 2020Article
- Computational screening for potential drug candidates against the SARS-CoV-2 main protease.F1000ResearchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.